Business
Board Changes
Board Changes.
About this update from Gunsynd Plc
[{"type":"text","content":"\n Syntopix Group plc\n13 December 2006\n\n\n\nFor immediate release 13 December 2006\n\n\n SYNTOPIX GROUP PLC\n ('Syntopix' or 'the Group')\n\n BOARD CHANGES\n\n\nSyntopix Group plc (AIM: SYN), the drug discovery and development group focused\non dermatological diseases, is pleased to announce that Stephen Philip Jones BSc\n(Hons) Pharm, PhD, MRPharmS, (aged 49), has been appointed as Chief Executive\nOfficer (having been Chief Operating Officer since 1 July 2006). The appointment\nis effective from 1 January 2007. At the same time Rod Adams (Chief Executive\nOfficer) has been appointed as Chairman of the Company and Gwyn Humphreys has\nbeen appointed as the Company's senior non-executive Director.\n\nThere are no further disclosures to be made in accordance with Schedule 2 (g) of\nthe AIM rules.\n\nCommenting on the Board changes, Rod Adams, said: 'I am delighted that Stephen\nhas taken the position of Chief Executive. Stephen has grown into this role\nhaving spent six months working at Syntopix and I believe that his experience at\nGSK in drug development and consumer healthcare will stand him in good stead to\ntake the business forward. I am pleased to be taking over as Chairman and look\nforward to continuing to work alongside Stephen and the Syntopix management\nteam. We are all delighted that Gwyn is staying on the Syntopix Board as a\nsenior non-executive Director and I would like to thank him for his hard work\nand support as Chairman. We have a solid management team in place to take the\nCompany and the exciting products within our portfolio through clinical\ndevelopment.'\n\n\n ENDS\n\n\nFor further information please contact:\n\n\nSyntopix Group plc 0845 125 9204\nStephen Jones, Chief Executive officer\nRod Adams, Chairman\n\nKBC Peel Hunt Ltd 020 7418 8900\nMegan MacIntyre\n\nBuchanan Communications 020 7466 5000\nMary-Jane Johnson\n\n\n\nNotes to editors\n\n\nAbout Syntopix Group plc\n\nSyntopix, a group focused on the discovery and development of drugs for the\ntopical treatment of dermatological diseases, was founded in 2003 as a spin-out\nfrom the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the leading\nexperts in skin microbiology, with initial funding from The Wellcome Trust.\n\nSyntopix' strategy is to seek to reduce the risks and costs of drug discovery\nand development by discovering novel u...